Orrick represented JMP Securities and Ladenburg Thalmann as underwriters of a follow-on public offering of 6,000,000 shares of common stock by Axogen, Inc. (“Axogen”), resulting in gross proceeds to the company of $18 million excluding any exercise by the underwriters of their option to purchase additional shares. In connection with the offering, Axogen’s common stock was approved for uplisting from the OTCQB Marketplace to the NASDAQ Capital Market.
AxoGen (NASDAQ: AXGN), a regenerative medicine company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration. The net proceeds to the company from the offering are expected to be used for continued product commercialization and marketing efforts, development of product pipeline and for general working capital purposes.
The Orrick team advising on this transaction was led by Capital Markets partner Andrew Thorpe and senior associate Stephen Ashley.